cerrar

BOC Sciences

Last updated: 18.10.2021

Company Name: BOC Sciences

Telephone Number: 1-631-485-4226

Fax: 1-631-614-7828
Address: Ramsey Road, Shirley, NY 11967, USA
Description:
BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make the best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.
Products:
BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.Over eight years of successful operation in the pharmaceutical industry has enabled us to possess a full-bodied array of building blocks in numerous pack sizes. BOC Sciences is constantly seeking to expand our product lines by incorporating additional potential drug-like molecules.

Services:
BOC Sciences provides a wide range of services to support the pharmaceutical industry through all stages of drug discovery including Custom Synthesis of those chemicals that are not in stock, Isotope Labeling Service, Chiral Synthesis and Resolution, Bioconjugation, PEGylation services, analytical services.Our capacity to provide pharmaceutical discovery services across the entire spectrum of the drug discovery process has assisted many of our esteemed clients in reaching their R&D goals. We are actively improving our capabilities and capacity through new expansions in BOC Sciences’s global business.

As a leading provider of building blocks, synthetic intermediates, and custom synthesis, BOC Sciences is committed to supplying cost-effective products and services, which are being utilized by our customers worldwide in molecule discovery on a daily basis to promote innovations in various industries.

Related

Eli Lilly’s Amazon Deal & Future of Online Pharmacies

Online pharmacies have still not captured a large share of the fragmented US pharma market, but Eli Lilly’s partnership with Amazon after a direct-sale initiative of its own may serve…

Small Biotechs Still Struggling to Find Vaccine Breakthroughs

The COVID-19 pandemic looked like a turning point for vaccines, but while R&D has made tremendous strides with ground-breaking platform technologies and mRNA, vaccines continue to attract fewer investments than…

Animal-Derived Ingredients in Medicines: A Call to Action

Writing in the March 2024 edition of the DIA Global Forum magazine, Scott P. Commins of the University of North Carolina School of Medicine, Jasmine Uchi of VeganMed, and Sachin…

BIO Chair Ted Love on IRA, US Election Outcomes & the Biosecure Act

At the American trade association’s latest CEO & Investor Conference, the board chair of the Biotechnology Innovation Organization (BIO) Ted W. Love discussed US policies and speculated about the impact…

Why Pharma Needs to Think Like Tarantino

Drawing inspiration from Quentin Tarantino’s directorial breakthrough in the early 1990s, Blue Spoon Consulting’s John Singer explores the pharma sector’s urgent need for a strategic overhaul to ensure success and…

Gilead CEO Named New PhRMA Board Chair; Inherits a Litany of Challenges

The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the…

US Drug Pricing and Reimbursement: Players, Payers, PBMs, and Prospects

In late 2023, The Wall Street Journal published the article Generic Drugs Should Be Cheap, but Insurers Are Charging Thousands of Dollars for Them. This article examined interactions between patient health insurance prescription…

New US ‘Biosecure Act’ to Target Chinese Biotechs WuXi and BGI

US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is…

2023 FDA Drug Approvals: Second Highest Count in 30 Years

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…

JP Morgan 2024 In Review: Good Vibrations

Cardiff Advisory’s David H. Crean outlines the positive atmosphere and sentiment observed at JPM 2024, the annual healthcare financing conference held near San Francisco’s Union Square. Dr. Crean picks up…

A Call for Collective Responsibility in Rare Disease Communities

Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the…

The IRA & Uncertain Times for US Pharma

As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here